Abstract
Vaccination plays an important role in large-scale commercial fish farming and has been a key reason for the success of salmon cultivation. In addition to salmon and trout, commercial vaccines are available for channel catfish, European seabass and seabream, Japanese amberjack and yellowtail, tilapia and Atlantic cod. In general, empirically developed vaccines based on inactivated bacterial pathogens have proven to be very efficacious in fish. Fewer commercially available viral vaccines and no parasite vaccines exist. Substantial efficacy data are available for new fish vaccines and advanced technology has been implemented. However, before such vaccines can be successfully commercialized, several hurdles have to be overcome regarding the production of cheap but effective antigens and adjuvants, while bearing in mind environmental and associated regulatory concerns (e.g., those that limit the use of live vaccines). Pharmaceutical companies have performed a considerable amount of research on fish vaccines, however, limited information is available in scientific publications. In addition, salmonids dominate both the literature and commercial focus, despite their relatively small contribution to the total volume of farmed fish in the world. This review provides an overview of the fish vaccines that are currently commercially available and some viewpoints on how the field is likely to evolve in the near future.
Acknowledgements
Information regarding commercial fish vaccines worldwide would have been difficult to obtain without the invaluable assistance from colleagues in Intervet. In particular William Enright, Oscar Parra, Luc Grisez, Marian McLoughlin, Roy Olav Hovlid and Kari Thorsø are thanked for their effort. Dag H Knappskog, Frank Nilsen and Stephane Villoing are acknowledged for valuable comments during the preparation of this manuscript and Irene Nygård for making the collage.